Form 4: 89bio CEO Disposes Equity in Roche Merger

89bio, Inc. CEO Rohan Palekar disposed of all his common stock and derivative securities following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR per share.

Summary

• Rohan Palekar, CEO and Director of 89bio, Inc., reported changes in beneficial ownership due to the company's acquisition by Roche Holdings, Inc. (via Bluefin Merger Subsidiary, Inc.).
• The merger was completed on October 30, 2025, with 89bio, Inc. becoming a wholly-owned subsidiary of Roche Holdings, Inc.
• Palekar acquired 125,000 shares from the settlement of performance-based restricted stock units (RSUs) and 1,203 shares from the Employee Stock Purchase Plan (ESPP) on October 22, 2025.
• Immediately prior to the merger, Palekar beneficially owned 934,273 shares of common stock.
• All 934,273 shares of common stock were disposed of in the merger for an offer price of $14.50 per share in cash, plus one non-tradeable Contingent Value Right (CVR) per share, representing the right to receive up to an aggregate of $6.00 per share upon achievement of specified milestones.
• All outstanding stock options held by Palekar, totaling 2,599,223 underlying shares, were cancelled or converted according to the merger terms on October 30, 2025.
• Options with an exercise price equal to or greater than $20.50 were cancelled immediately prior to the merger without any payment.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing liquidity and potential upside for shareholders. However, the contingent nature of CVRs and the cancellation of some options without value temper the overall positive sentiment.

Positives

• Successful completion of the merger provides liquidity to 89bio, Inc. shareholders.
• Shareholders received a guaranteed cash payment of $14.50 per share.
• Potential for additional value up to $6.00 per share via CVRs upon milestone achievement.
• Restricted stock units and performance-based restricted stock units held by the reporting person became fully vested upon the merger.
• In-the-money stock options were converted into cash and CVRs, providing value to the option holder.

Negatives

• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment.
• The Contingent Value Rights (CVRs) are non-tradeable, limiting immediate liquidity for the contingent portion of the consideration.
• 89bio, Inc. ceases to be an independent publicly traded company.

Risks

• The full value of the CVRs (up to $6.00 per share) is contingent on the achievement of specified milestones, which are not guaranteed.
• Former shareholders bear the risk that milestones may not be met, resulting in a lower total consideration than the maximum potential offer price.

Future Outlook

The filing primarily details the completed acquisition of 89bio, Inc. by Roche Holdings, Inc., and the subsequent disposition of equity by a key executive. The future outlook for 89bio, Inc. as an independent entity is no longer applicable, as it is now a wholly-owned subsidiary of Roche. The future value for former 89bio shareholders holding CVRs depends on the achievement of specified milestones.

Industry Context

This acquisition reflects the ongoing trend of larger pharmaceutical companies acquiring smaller biotechnology firms to bolster their pipelines, particularly in areas of unmet medical need. The use of Contingent Value Rights (CVRs) is a common mechanism in such deals to bridge valuation gaps and share future development risks and rewards, especially for assets in clinical development.

Comparison to Industry Standards

• The offer price of $14.50 cash plus a CVR up to $6.00 per share (total potential $20.50) is a common structure for biotech acquisitions, often seen in deals where the target company has promising assets but still requires significant development or regulatory hurdles.
• Comparable acquisitions in the biotech sector often involve a significant upfront cash component combined with contingent payments tied to clinical trial success, regulatory approvals, or sales milestones. For example, similar structures have been observed in deals like Merck's acquisition of Acceleron Pharma or Bristol Myers Squibb's acquisition of MyoKardia, where CVRs were used to provide additional value based on future drug performance.
• The cancellation of out-of-the-money options (exercise price equal to or greater than $20.50) without payment is standard practice in M&A transactions, reflecting that these options held no intrinsic value relative to the maximum potential deal consideration.

Stakeholder Impact

• **Shareholders:** Received $14.50 cash per share plus a CVR potentially worth up to $6.00 per share, providing liquidity and potential future upside.
• **Employees:** The merger likely impacts employees of 89bio, Inc., though specific details are not provided in this filing. Equity awards (RSUs, options) were treated according to the merger agreement.
• **Customers/Suppliers:** No direct impact mentioned, but 89bio's operations will now be under Roche's umbrella.

Next Steps

• Former 89bio shareholders holding CVRs will await the achievement of specified milestones for potential additional payments.
• Roche Holdings, Inc. will integrate 89bio, Inc. into its operations.

Key Dates

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Form 4, Rohan Palekar, CEO, Stock Options, RSUs, Contingent Value Rights, CVR, Beneficial Ownership, Biotechnology, Pharmaceuticals